Plexiform Arteriopathy in Rodent Models of Pulmonary Arterial Hypertension

Brandon L. Carman, Dan N. Predescu, Roberto Machado, Sanda A. Predescu

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

As time progresses, our understanding of disease pathology is propelled forward by technological advancements. Much of the advancements that aid in understanding disease mechanics are based on animal studies. Unfortunately, animal models often fail to recapitulate the entirety of the human disease. This is especially true with animal models used to study pulmonary arterial hypertension (PAH), a disease with two distinct phases. The first phase is defined by nonspecific medial and adventitial thickening of the pulmonary artery and is commonly reproduced in animal models, including the classic models (ie, hypoxia-induced pulmonary hypertension and monocrotaline lung injury model). However, many animal models, including the classic models, fail to capture the progressive, or second, phase of PAH. This is a stage defined by plexogenic arteriopathy, resulting in obliteration and occlusion of the small- to mid-sized pulmonary vessels. Each of these two phases results in severe pulmonary hypertension that directly leads to right ventricular hypertrophy, decompensated right-sided heart failure, and death. Fortunately, newly developed animal models have begun to address the second, more severe, side of PAH and aid in our ability to develop new therapeutics. Moreover, p38 mitogen-activated protein kinase activation emerges as a central molecular mediator of plexiform lesions in both experimental models and human disease. Therefore, this review will focus on plexiform arteriopathy in experimental animal models of PAH.

Original languageEnglish (US)
Pages (from-to)1133-1144
Number of pages12
JournalAmerican Journal of Pathology
Volume189
Issue number6
DOIs
StatePublished - Jun 2019

    Fingerprint

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this